Alimera Sciences Reports Q1 Loss, Misses Revenue Estimates
Ovid Therapeutics GAAP EPS of -$0.17
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.